Soros Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Soros Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-160,000	Closed	-$3.28M	–	202
2018 Q3	$3.45M	Hold	160,000	–	–	0.08%	148
2018 Q2	$3.89M	Buy	+160,000	New	+$3.26M	0.06%	176
2015 Q3	–	Sell	-423,308	Closed	-$25M	–	284
2015 Q2	$25M	Buy	+423,308	New	+$26.1M	0.23%	100
2015 Q1	–	Sell	-4,859,966	Closed	-$279M	–	247
2014 Q4	$279M	Sell	4,859,966 -1,371,756	-22%	-$76.4M	3.05%	3
2014 Q3	$335M	Sell	6,231,722 -1,041,518	-14%	-$55.2M	2.5%	5
2014 Q2	$381M	Sell	7,273,240 -3,036,801	-29%	-$155M	2.87%	4
2014 Q1	$545M	Buy	10,310,041 +994,041	+11%	+$45.9M	5.38%	1
2013 Q4	$373M	Buy	9,316,000 +5,708,000	+158%	+$225M	3.17%	3
2013 Q3	$136M	Buy	+3,608,000	New	+$141M	1.49%	20

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soros Fund Management's TEVA Position: Q4 2018 in Review

Soros Fund Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 160,000 shares — an estimated $3.28M sold.

Soros Fund Management first reported a position in TEVA in Q3 2013 and held it in 9 quarters. The position peaked at $545M in Q1 2014. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Soros Fund Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Soros Fund Management sold 160,000 Teva Pharmaceuticals shares in Q4 2018, an estimated $3.28M.
Soros Fund Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 9 quarters.
Soros Fund Management's Teva Pharmaceuticals position peaked at $545M in Q1 2014.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Soros Fund Management's 13F filing for Q4 2018, filed 14 Feb 2019.